Speech by Federal Chancellor Dr. Angela Merkel at the celebration "100 Years of Fresenius" on October 1, 2012, in Frankfurt am Main:

Germany Angela Merkel · Former Chancellor of Germany

1 October 2012 · Celebration of 100 Years of Fresenius · Frankfurt am Main, Germany

Context
Merkel addressed guests at Fresenius's 100th anniversary celebration on October 1, 2012, in Frankfurt am Main, honoring the company's growth into a global healthcare corporation.
Main themes
Fresenius centenary celebration, German corporate history, globalization and internationalization, healthcare industry, entrepreneurial success, Else Kröner's legacy, corporate social responsibility, transatlantic business relations, medical innovation, family business transformation
Duration
~15 min
52nd percentile
Words
1,817
52nd percentile
Sentences
99
62nd percentile
Readability
43
44th percentile
Grade
11.6
40th percentile
Syntax
2.97
44th percentile
Vocabulary
2.09
25th percentile

Translated from German

Content
Actors
Style

The broad sphere of national life a sentence belongs to. Every sentence has an Arena, so it is the denominator the other indices are read against.

Other
  • Economic 40%38%
  • Social 32%31%
  • Ceremonial 25%24%
  • Technological 2%2%
  • Institutional 1%1%
  • Geopolitical 0%0%
  • Environmental 0%0%
  • Not in focus 3%

99 sentences in 36 paragraphs

Dear Mr. Krick,

dear Mr. Schneider,

Mr. Ambassador,

esteemed Minister Kühne-Hörmann,

ladies and gentlemen,

valued assembly,

from a pharmacy – as you could see upon entering – to a globally operating healthcare corporation – that is 100 years of Fresenius in a nutshell. That is 100 years of an impressive German corporate and entrepreneurial history.

That is why I am very pleased to be here today, as it is a truly substantial part of successful German corporate history. It is a story that shows how the visions of those who want to undertake something become reality. Therefore, I would like to extend my heartfelt congratulations to all approximately 160,000 employees for being part of this company, and I wish you all the best on this anniversary.

It was in 1912 when Dr. Eduard Fresenius – as we have heard – laid the foundation for a corporate ascent that would ultimately make his name a globally recognized trademark. Here in Frankfurt, the resourceful pharmacist expanded his laboratory and founded a small production facility. Among his specialties were injection solutions and Bormelin nasal ointment.

Now we see what can come of it. For today, the company sets global standards in dialysis, infusion therapy, and clinical nutrition, as well as in medical technology and hospital management.

A business magazine has honored you for your impressive growth story, stating: This is "the rocket from Bad Homburg." The World Group awarded you this year with the "TOP 500 Award" for "strategic foresight and outstanding entrepreneurial performance."

It is quite evident that the chemistry is right in your company. For in your laboratories, you seem to have found the recipe for how solid values such as quality and reliability can repeatedly be combined with the courage to take risks into a successful solution.

Behind the success story of Fresenius, alongside the founder and namesake, is also a strong woman: his adopted daughter Else Kröner – yes, women should always be applauded. Shortly after the war, she took on responsibility for the business. That was certainly no easy undertaking. Yet she succeeded – later also together with her husband – not only in securing the existence of the company but also in gradually transforming the medium-sized family business into a company of international renown.

Moreover, Else Kröner not only ensured economic growth but also embodied lived responsibility. Her wealth was to serve the public good. The foundation established from it is therefore also dedicated to the promotion of science. It supports medical humanitarian aid projects. And the foundation, as the largest shareholder of Fresenius, is also a guarantor of value orientation in corporate policy. I believe this is a piece of German corporate culture that we find in many places. For that, a heartfelt thank you!

Fresenius exemplifies the opportunities that increasing globalization holds – both from a business perspective and an economic perspective. For the openness of German companies to the world and their international competitiveness has contributed significantly to our country's prosperity.

Fresenius recognized the opportunities of internationalization early on and focused on emerging economies. For example, engagement in Brazil began as early as the 1970s, followed by engagement in China in the 1980s. I deeply regret that I will not be able to see the film about your engagement in China personally later. However, I have already received confirmation that it will be sent to me.

Even today, Fresenius conducts significant research, development, and production in Germany, but is now represented in over 100 countries. We have already heard about your engagement in the United States. I am very grateful that you, as a company, represent such an important transatlantic bridge. I believe we cannot have enough of that.

For Fresenius, the merger with the comparatively larger company National Medical Care in 1996 was certainly a milestone in its international engagement. With around 41 percent of revenue and about 32 percent of employees, North America is now the most important region for the group after Europe.

Fresenius enjoys a good reputation everywhere – in all its areas. Traditionally, particularly inpatient care is in the spotlight of public attention: 72 Helios hospitals, 43,000 employees. I have recently also encountered Fresenius in my own constituency: with locations in Stralsund and Ahrenshoop. This means you are, so to speak, under the constant observation of the constituency representative Merkel. Let this be a promise to you.

Now, you are operating in a field that increasingly intersects with nearly all the controversial issues that society has to offer. I do not know how it was 100 years ago, but today it is nice that politicians are still invited when it comes to the healthcare system. In this regard, I appreciate that.

Considering that you must know a hundred or more healthcare systems around the world and find access everywhere to see how you can engage there, I express my great respect to you. I have dealt a lot with health reforms in my political life and therefore know how difficult it is – as Mr. Dr. Schneider has also pointed out: on one hand, you have the area that has so much to do with security for people, with solidarity in society, and on the other hand, the pressure that limited financial resources naturally require economic efficiency.

It is about continually bringing both together – under the overarching theme of trust that a company like yours must represent. We know how quickly such trust can be lost. All the more, I must congratulate you that over 100 years you have continued to build this trust and not diminish it. That is not so easy.

You are in an industry that, on one hand, is of particular importance given the demographic developments in highly industrialized countries, and partly also in emerging countries, but on the other hand, also in light of the growing global population. There is, on one hand, the ever-present medical and technological progress, and on the other hand, the expectation of every citizen to receive the necessary medical care. This is a huge task for politics that we could not master at all if we did not have companies that are also dedicated to this task. In this respect, we are trying to make your framework conditions bearable.

I do not want to talk long about proportional orientation values that will be available starting in 2013. I also do not want to remind you that we have structured the tariff wage refinancing in such a way that the employees in the hospitals are hopefully still well motivated. But all of this concerns your tasks that you have to solve daily. These are all areas in which you must make decisions every day or push for them to be made.

Like all companies, you are currently operating in a challenging economic environment. The debt crisis in the Eurozone shapes our daily news landscape, but it primarily shapes the reality in many European countries. Germany is currently an anchor of stability, but Germany, with 60 percent of its exports going to European neighboring countries and 40 percent of its exports to the Eurozone, is of course not disconnected from this.

All the more, I would like to thank you for continuing to actively drive innovation, for at its core – as Ambassador Murphy has already mentioned – it is about the question of what role Europe and also the United States will play in the future in a rapidly developing world.

The member states of the European Union still account for about seven to eight percent of the world’s population. We still produce about 25 percent of the world’s gross domestic product today. And we have about 50 percent of the world’s social spending. If we want to maintain this in Europe, it is an absolute necessity that we invest in innovation, that we remain creative, that we never settle for the present, but that we push things forward.

That is why, as a federal government – as the minister has said – we have planned around four billion euros annually in this legislative period for research, development, and education – out of the deep conviction that we can only maintain our prosperity if we are willing to invest in new things.

That is why we are partners. Politics sets the framework conditions. But without companies that also make something out of it, that undertake something with it, we cannot move forward at all. One of the great tasks is to use the money allocated for research and development in such a way that it also leads to economic growth.

I believe that our high-tech strategy in the research sector and the associated framework program for health research are the right approach. I am pleased that Hesse is a state that actively makes use of these opportunities and is therefore also the location of many research activities.

Innovation in the field of health also means taking advantage of the opportunities presented by information technologies. The combination of classical medical technology with information and communication technology will be one of the answers to an aging society – to a society in which medical care must be ensured at a high level, especially in rural areas, using new methods. Therefore, we will also place a special emphasis on this topic at our annual IT summit.

Everything is only possible if we have well-qualified professionals. We have a lot to do in Germany to convince people to pursue careers in the natural sciences, engineering, or technical fields. The issue of skilled labor shortages will occupy us significantly in light of the demographic developments in Germany in the coming years. All the more important it is that we have companies that pull together with us and inspire enthusiasm for these professions, just as for medical and caregiving professions.

Given what can be done in the field of health, Fresenius has a brilliant perspective ahead, as the expectations of people regarding their own health will remain – rightly so. The technical and medical possibilities will grow. We will all tend to live longer. This means that many tasks will also come your way in the coming years.

For there are not only the technical questions to be addressed. There are also the many ethical questions associated with the beginning and end of life. What I can offer you is a partnership between business and politics in all these matters where it is necessary, and where it is helpful for both of us.

Therefore, I wish first and foremost Fresenius as a company good health. I wish the employees good health so that they can work energetically for this wonderful company. And I ask that you do everything for health in the countries where you operate.

All the best, once again congratulations on the 100th anniversary, have a pleasant evening, and above all: Here’s to the next 100 years! Full speed ahead!